2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers

dc.contributor.author
Suárez-Calvet, Marc
dc.contributor.author
Kleinberger, Gernot
dc.contributor.author
Araque Caballero, Miguel Ángel
dc.contributor.author
Brendel, Matthias
dc.contributor.author
Rominger, Axel
dc.contributor.author
Alcolea, Daniel
dc.contributor.author
Fortea, Juan
dc.contributor.author
Lleó, Alberto
dc.contributor.author
Blesa, Rafael
dc.contributor.author
Gispert, Juan Domingo
dc.contributor.author
Sanchez-Valle, Raquel
dc.contributor.author
Antonell, Anna
dc.contributor.author
Rami Gonzalez, Lorena
dc.contributor.author
Molinuevo, José Luis
dc.contributor.author
Brosseron, Frederic
dc.contributor.author
Traschütz, Andreas
dc.contributor.author
Heneka, Michael
dc.contributor.author
Struyfs, Hanne
dc.contributor.author
Engelborghs, Sebastiaan
dc.contributor.author
Sleegers, Kristel
dc.contributor.author
Van Broeckhoven, Christine
dc.contributor.author
Zetterberg, Henrik
dc.contributor.author
Nellgård, Bengt
dc.contributor.author
Blennow, Kaj
dc.contributor.author
Crispin, Alexander
dc.contributor.author
Ewers, Michael
dc.contributor.author
Haass, Christian
dc.contributor.author
Universitat Autònoma de Barcelona
dc.date.issued
2016
dc.identifier
https://ddd.uab.cat/record/185818
dc.identifier
urn:10.15252/emmm.201506123
dc.identifier
urn:oai:ddd.uab.cat:185818
dc.identifier
urn:pmid:26941262
dc.identifier
urn:pmcid:PMC5120370
dc.identifier
urn:pmc-uid:5120370
dc.identifier
urn:articleid:17574684v8p466
dc.identifier
urn:oai:egreta.uab.cat:publications/d5f9496f-f35b-4753-b3fe-0a93b6261cc6
dc.identifier
urn:scopus_id:84960155154
dc.identifier
urn:oai:pubmedcentral.nih.gov:5120370
dc.description.abstract
2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations of 2 are associated with increased risk of Alzheimer's disease (). 2 is a type-1 protein with an ectodomain that is proteolytically cleaved and released into the extracellular space as a soluble variant (2), which can be measured in the cerebrospinal fluid (). In this cross-sectional multicenter study, we investigated whether levels of 2 are changed during the clinical course of , and in cognitively normal individuals with suspected non- pathology (). 2 levels were higher in mild cognitive impairment due to than in all other groups and controls. individuals also had significantly increased 2 compared to controls. Moreover, increased 2 levels were associated with higher total tau and phospho-tau, which are markers of neuronal degeneration and tau pathology. Our data demonstrate that 2 levels are increased in the early symptomatic phase of , probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration.
dc.format
application/pdf
dc.language
eng
dc.publisher
dc.relation
European Commission P7-2007-2013
dc.relation
EMBO Molecular Medicine ; Vol. 8 (march 2016), p. 466-476
dc.rights
open access
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.subject
Alzheimer's disease
dc.subject
Biomarkers
dc.subject
Microglia
dc.subject
Neurodegeneration
dc.subject
TREM2
dc.subject
Biomarkers & Diagnostic Imaging
dc.subject
Neuroscience
dc.title
2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers
dc.type
Article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)